Skip to contentC
Cytek Biosciences, Inc.
C
CTKBCytek Biosciences, Inc. Released Nov 8, 2021, after the close
10-Q filed Nov 12, 2021, 43 days after period end · 0000950170-21-004256
Q3 2021 · 10-Q
Revenue$34.38M$34.38M+37.0% vs Q3 2020+13.0% vs Q2 2021 Net Income$1.42M$1.42M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR
−46.8% vs Q2 2021
EPS Diluted$0.00$0.00−100.0% vs Q3 2020no prior Q2 2021 on file Gross Profit$21,277,000+36.3% Operating Income$2,897,000−56.8% Operating Cash Flowderived$1,161,000−47.0% Free Cash Flowderived-$147,000N/M Margins · derivedGross margin61.9%−0.3 pt vs Q3 2020
Operating margin8.4%−18.3 pt vs Q3 2020
Net margin4.1%−21.9 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 12, 2021 · 43 d after period end